A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease | MicrobiomeTrials
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-12-19Est. Completion: 2026-12-23
Enrollment target: 84 participants
Locations
Investigational Site Number : 8400007, Birmingham, Alabama, United States
Investigational Site Number : 8400015, Orange, California, United States
Investigational Site Number : 8400012, San Francisco, California, United States
Investigational Site Number : 8400025, Tampa, Florida, United States
Emory Children's Center- Site Number : 8400020, Atlanta, Georgia, United States
Investigational Site Number : 8400014, Chicago, Illinois, United States
Investigational Site Number : 8400017, Hinsdale, Illinois, United States
Investigational Site Number : 8400010, Ann Arbor, Michigan, United States
Investigational Site Number : 8400019, Edina, Minnesota, United States
Investigational Site Number : 8400018, Las Vegas, Nevada, United States
Investigational Site Number: 8400028, Albuquerque, New Mexico, United States
Investigational Site Number : 8400001, New York, New York, United States
Investigational Site Number : 8400021, Chapel Hill, North Carolina, United States
Investigational Site Number : 8400024, Dallas, Texas, United States
Investigational Site Number : 8400005, El Paso, Texas, United States
Other microbiome trials you might be interested in